WISP1 drives a mechanically active immune modulatory and proliferative cardiac myofibroblast state

This study demonstrates that WISP1 drives a unique, P38 MAPK-dependent myofibroblast phenotype characterized by proliferation and immune modulation, distinct from the canonical TGF{beta}1-mediated fibrotic program, thereby promoting pathological cardiac remodeling through non-canonical signaling pathways.

The Gist

The Big Picture: The Heart's "Construction Crew"

Imagine your heart is a busy city. When the city gets damaged (like after a heart attack), it needs a construction crew to fix the broken roads and buildings. In the heart, this crew is made of cells called fibroblasts.

Usually, when these workers get the "fix it" signal, they transform into super-workers called myofibroblasts. Their job is to lay down strong concrete (collagen) to patch the hole and tighten the structure so the heart doesn't fall apart.

For a long time, scientists thought there was only one boss who gave the orders to start this construction: a protein called TGFβ1. They thought TGFβ1 told the workers to stop moving around, get serious, and start pouring concrete.

This paper discovered a second, very different boss: a protein called WISP1.

The Plot Twist: Two Different Bosses, Two Different Styles

The researchers found that while WISP1 also tells the construction crew to start working, it gives them a completely different set of instructions than TGFβ1 does.

Here is the difference:

1. The "Classic" Boss (TGFβ1)

• The Vibe: "Stop everything! Get serious! Build a wall!"
• The Action: This boss tells the cells to become rigid, stop dividing, and focus entirely on laying down heavy concrete (collagen) and a specific marker called Periostin (think of this as the "Official Construction Badge").
• The Result: A classic, stiff scar.

2. The "New" Boss (WISP1)

• The Vibe: "Let's get busy! Move around! Talk to the neighbors!"
• The Action: WISP1 tells the cells to:
  • Multiply: It makes the workers reproduce rapidly (proliferation).
  • Move: It helps them close wounds quickly.
  • Talk: It turns on the "radio," making the cells release signals that talk to the immune system (inflammation).
  • Build: It does make them lay down some concrete, but it does NOT make them wear the "Official Construction Badge" (Periostin).
• The Result: A worker that is active, chatty, and multiplying, but isn't quite the same "stiff scar" builder as the classic type.

The Secret Mechanism: Different Engines

The scientists wanted to know how these two bosses give different orders. They found that the workers use different engines to run the show:

• TGFβ1 uses the "Classic Engine" (a pathway scientists call SMAD).
• WISP1 uses a different engine called p38 MAPK.

The Analogy: Imagine TGFβ1 is a diesel truck and WISP1 is a sports car. Both can get you to the construction site, but they run on different fuel and have different engines. If you put a blockage in the sports car's engine (inhibiting p38), the sports car stops, but the diesel truck keeps right on going. This proves they are doing their jobs in totally different ways.

The "Multi-Omics" Detective Work

To really understand what was happening, the researchers didn't just look at the workers; they looked at the workers' blueprints (RNA) and their toolboxes (Proteins).

• The Blueprints (RNA): When WISP1 was in charge, the blueprints were full of instructions for "How to multiply" and "How to talk to the immune system." There were very few instructions for "How to make a stiff scar."
• The Toolboxes (Proteins):
  • Inside the cell (the cytosol), the tools were all about growth and division.
  • Outside the cell (the ECM), the tools were all about inflammation and immune signaling.
  • Crucially, the "stiff scar" tools were missing or very weak compared to when TGFβ1 was in charge.

Why Does This Matter?

For years, scientists thought WISP1 was just another "scar-maker." This paper changes the story.

The New Story: WISP1 creates a unique type of worker. It's a worker that is mechanically active (it pulls and tightens) and lays down some concrete, but its main superpower is communicating with the immune system and growing.

The Takeaway:
Think of heart repair not as a single construction project, but as a complex dance.

• TGFβ1 is the foreman who says, "Build the wall."
• WISP1 is the project manager who says, "Hire more workers, keep the site active, and call the security team (immune system) to help."

If we want to stop heart failure, we can't just block one boss. We need to understand that WISP1 is driving a specific, immune-focused type of repair that is different from the classic scarring process. This opens up new doors for medicines that might target WISP1 to stop the bad kind of inflammation without stopping the good kind of healing.

Summary in One Sentence

WISP1 is a unique protein that turns heart cells into active, immune-communicating repair workers, using a different engine than the classic "scar-maker" protein, proving that heart repair is more complex and diverse than we previously thought.

Technical Summary

1. Problem Statement

Pathological cardiac remodeling, characterized by fibrosis, is a primary driver of heart failure. This process involves the differentiation of quiescent cardiac fibroblasts into activated myofibroblasts, which deposit excessive extracellular matrix (ECM), leading to tissue stiffening and dysfunction.

• The Gap: While Transforming Growth Factor-beta 1 (TGFβ1) is the canonical mediator of myofibroblast activation, the specific role of the matricellular protein WISP1 (CCN4) remains poorly defined. Previous studies suggest WISP1 is upregulated after myocardial infarction (MI) and promotes fibrosis, but the signaling mechanisms, its relationship with TGFβ1, and the precise phenotypic state of WISP1-activated fibroblasts are unknown.
• The Question: Does WISP1 drive a canonical TGFβ1-like fibrotic phenotype, or does it induce a distinct cell state? What are the underlying signaling pathways and multi-omic signatures?

2. Methodology

The authors employed a rigorous multi-omics approach combining functional assays, molecular biology, and high-throughput sequencing/proteomics using primary murine cardiac fibroblasts (CFs) isolated from adult C57BL/6 mice (both male and female).

• Cell Culture & Treatment: Primary CFs were treated with recombinant human TGFβ1 (10 ng/mL), recombinant murine WISP1 (500 ng/mL), or a combination for 72 hours.
• Functional Assays:
  • Contractility: Collagen gel contraction assays.
  • Migration: Scratch wound healing assays.
  • ECM Deposition: Picrosirius red staining for total collagen and Western blotting/qPCR for specific markers (α-SMA, Col1a1, Periostin).
  • Signaling Inhibition: Use of SB203580 (p38 MAPK inhibitor) to delineate signaling pathways.
• Multi-Omics Profiling:
  • Transcriptomics: Bulk RNA-seq followed by Gene Set Enrichment Analysis (GSEA) using MSigDB Hallmark gene sets.
  • Proteomics: Label-free quantitative mass spectrometry (LC-MS/MS) performed on two distinct fractions:
    1. Global/Soluble Proteome: Cytosolic and nuclear proteins.
    2. ECM Proteome: Decellularized matrix proteins.
  • Bioinformatics: Differential expression analysis using DESeq2 (RNA) and limma (Proteomics), with specific attention to compartment-specific enrichment.

3. Key Contributions

1. Phenotypic Divergence: The study establishes that WISP1 drives a unique myofibroblast state that is mechanically active but transcriptionally distinct from the canonical TGFβ1-driven fibrotic state.
2. Signaling Mechanism: Identification of a non-canonical p38 MAPK-dependent pathway as the primary driver of WISP1-mediated activation, contrasting with TGFβ1's canonical pathways.
3. Multi-Compartmental Resolution: The study provides a novel view of fibroblast activity by separating the intracellular (proliferative) and extracellular (immune-modulatory) proteomic effects of WISP1, a level of resolution not previously achieved in this context.
4. Context-Dependent Interaction: Demonstration that WISP1 and TGFβ1 do not act additively; instead, they exhibit antagonistic interactions regarding proliferation and inflammation gene programs.

4. Key Results

A. Functional Activation and Marker Expression

• Mechanical Activity: WISP1 alone was sufficient to induce α-SMA expression, collagen type I secretion, collagen gel contraction, and wound closure.
• Synergy vs. Independence: While WISP1 enhanced TGFβ1-induced α-SMA and contractility, it did not further potentiate TGFβ1-induced collagen production.
• The "Missing" Marker: Crucially, WISP1 failed to induce Periostin (Postn), a hallmark marker of canonical myofibroblast differentiation. This suggests WISP1 activates a distinct, non-canonical cell state.

B. Signaling Pathway

• p38 MAPK Dependency: Inhibition of p38 MAPK (SB203580) completely ablated WISP1-induced α-SMA and collagen expression.
• Specificity: The same inhibitor had no effect on TGFβ1-induced α-SMA or Periostin, confirming that WISP1 and TGFβ1 utilize divergent signaling networks.

C. Transcriptomic Analysis (RNA-seq)

• WISP1 Signature: Enriched for proliferation (E2F targets, G2M checkpoint) and immune/inflammatory pathways (TNFα/NF-κB, IFNγ response).
• TGFβ1 Signature: Suppressed proliferation and inflammation while strongly upregulating canonical stress, fibrosis, and ECM organization pathways.
• Interaction: Co-treatment resulted in the antagonism of WISP1-driven proliferation/inflammation genes, suggesting TGFβ1 overrides the WISP1-specific transcriptional program.

D. Proteomic Analysis (Mass Spectrometry)

• Compartmentalization:
  • Intracellular (Global) Proteome: WISP1 drove a strong proliferative signature.
  • ECM Proteome: WISP1 drove a strong immune/inflammatory signature.
• Weak Canonical Fibrosis: Unlike TGFβ1, which robustly increased myofibroblast and ECM protein scores, WISP1 showed minimal induction of traditional ECM remodeling proteins, reinforcing the transcriptomic findings.

5. Significance and Implications

• Reconceptualizing WISP1: The paper repositions WISP1 from a simple "pro-fibrotic effector" downstream of TGFβ1 to a context-dependent regulator that induces a unique, immune-modulatory, and proliferative myofibroblast phenotype.
• Therapeutic Potential: Since WISP1 drives a state rich in immune signaling and proliferation rather than pure matrix stiffening, targeting WISP1 (or its p38 pathway) could potentially modulate the inflammatory phase of cardiac repair or prevent maladaptive remodeling without necessarily blocking the essential initial scar formation driven by TGFβ1.
• Mechanistic Insight: The findings explain why WISP1 is associated with fibrosis in vivo (due to collagen production) but fails to recapitulate the full canonical myofibroblast phenotype in vitro (lack of periostin). It suggests WISP1 may be critical for the early, dynamic phase of remodeling (cell recruitment, immune crosstalk, and initial contraction) rather than the late-stage maturation of the scar.
• Future Directions: The study highlights the need to investigate fibroblast-immune cell crosstalk mediated by WISP1 and the temporal/spatial coordination of WISP1 and TGFβ1 during cardiac injury.

In conclusion, this work utilizes a comprehensive multi-omics strategy to define a novel cardiac myofibroblast state driven by WISP1, characterized by mechanical activity coupled with immune modulation and proliferation, distinct from the classical TGFβ1-driven fibrotic phenotype.